Though malignant tumors are less dependent on CSF1 stimulation, exhibit more autonomous growth, and their treatment is sometimes further complicated by additional genetic alterations, given that both benign and malignant TSGCTs share the same underlying fusion, CSF1R inhibition remains a central concept in therapeutic development. This evidence concerns the gene CSF1R and cancer.